OXiGENE (OXGN) Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference
11/17/2009 11:20:40 AM
More...
|
OXiGENE (OXGN) Reports Third Quarter 2009 Financial Results
11/9/2009 11:37:56 AM
More...
|
OXiGENE (OXGN) Announces Third Quarter 2009 Earnings Conference Call and Webcast
11/3/2009 8:32:54 AM
More...
|
OXiGENE (OXGN) (JOBS) to Buy VaxGen, Inc. (VXGN) for About $22 Million in Stock
10/15/2009 6:38:11 AM
More...
|
OXiGENE (OXGN) Announces Data Presentation At 2009 AACR-EORTC-NCI Conference
10/12/2009 8:50:55 AM
More...
|
OXiGENE (OXGN) (JOBS) CEO Resigns
10/8/2009 6:44:37 AM
More...
|
OXiGENE (OXGN) Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position
7/30/2009 10:06:55 AM
More...
|
OXiGENE (OXGN) to Raise $10 Million in Registered Direct Offering
7/15/2009 8:23:19 AM
More...
|
OXiGENE (OXGN) Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology
7/6/2009 7:48:27 AM
More...
|
OXiGENE (OXGN) Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology
6/25/2009 9:43:28 AM
More...
|
|